Skip to content

Effect of dexmedetomidine on sleep quality and anxiety of breast cancer patients after operation

Effect of dexmedetomidine on sleep quality and anxiety of breast cancer patients after operation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094045
Enrollment
Unknown
Registered
2024-12-16
Start date
2024-12-16
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Intervention group:The PCIA regimen for the experimental group consists of dexmedetomidine (2.5 µg/kg) + sufentanil (2 µg/kg) + flurbiprofen axetil (3 mg/kg) + ondansetron 8 mg
The medications for both groups are prepared based on the total body weight of the patients and diluted with normal saline to a total volume of 100 ml. The parameters for the analgesia pump are set as
Control group:The control group’s PCIA regimen consists of sufentanil (2 µg/kg) + flurbiprofen axetil (3 mg/kg) + ondansetron 8 mg. The medications for both groups are prepared based on the total body

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Breast cancer patients scheduled for breast surgery in our hospital’s breast surgery department from December 2024 to April 2025; (2) Preoperative American Society of Anesthesiologists (ASA) physical status classification is between I and II; (3) Age between 18 and 60 years old; (4) Patients have a preoperative AIS score of >=4 points; (5) Complete clinical data; (6) Patients or their family have signed the informed consent for anesthesia and the informed consent for the study.

Exclusion criteria

Exclusion criteria: (1) Allergy to or contraindications for the medication used in this study; (2) Sick sinus syndrome, second-degree or third-degree heart block, or clinically significant sinus bradycardia; (3) Refusal to use patient-controlled intravenous analgesia (PCIA); (4) Long-term use of anticholinergic drugs, benzodiazepine sedatives, tricyclic antidepressants, antipsychotic drugs, antihistamines, H2 receptor antagonists, and opioid analgesics; (5) Preoperative diagnosis of chronic insomnia; (6) Preoperative chemotherapy for malignant tumors; (7) History of breast surgery; (8) BMI greater than 35; (9) Inability to cooperate in completing the scales.

Design outcomes

Primary

MeasureTime frame
Athens Insomnia Scale;Visual analogue scale;General information;

Secondary

MeasureTime frame
Hamilton Anxiety Scale;Quality of Recovery-15;Hemodynamic stability;

Countries

China

Contacts

Public ContactZheng Yan

China-Japan Union Hospital of Jilin University

zheng_y@jlu.edu.cn+86 133 3168 1363

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026